Low-Dose Colchicine Attenuates Sepsis-Induced Liver Injury: A Novel Method for Alleviating Systemic Inflammation

[1]  Teng Zhang,et al.  The immunomodulatory function of adenosine in sepsis , 2022, Frontiers in Immunology.

[2]  A. Khanolkar,et al.  Mechanisms and Modulation of Sepsis-Induced Immune Dysfunction in Children , 2021, Pediatric Research.

[3]  J. H. Lee,et al.  Immunomodulator use in paediatric severe sepsis and septic shock. , 2021, Annals of the Academy of Medicine, Singapore.

[4]  Z. Qiu,et al.  Pathogenic characteristics and treatment in 43 cases of acute colchicine poisoning. , 2021, Toxicology research.

[5]  Jian Sun,et al.  Gut-liver crosstalk in sepsis-induced liver injury , 2020, Critical Care.

[6]  S. Fatani,et al.  Association of TNF-α-308 (G >A) (rs1800629) Gene Polymorphism with Adverse Outcomes of Sepsis in Critically Ill Patients. , 2020, DNA and cell biology.

[7]  Y. Ilan,et al.  Introducing variability in targeting the microtubules: Review of current mechanisms and future directions in colchicine therapy , 2020, Pharmacology research & perspectives.

[8]  N. Dalbeth,et al.  Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials , 2020, Arthritis Research & Therapy.

[9]  A. Shibuya,et al.  Type 1 Innate Lymphoid Cells Protect Mice from Acute Liver Injury via Interferon-γ Secretion for Upregulating Bcl-xL Expression in Hepatocytes. , 2019, Immunity.

[10]  Y. Ilan.  Cell Biology International , 2019 .

[11]  Y. Ilan,et al.  The role of microtubules in the immune system and as potential targets for gut-based immunotherapy. , 2019, Molecular immunology.

[12]  L. Lunsford,et al.  Association of Corticosteroid Treatment With Outcomes in Adult Patients With Sepsis: A Systematic Review and Meta-analysis , 2019, JAMA internal medicine.

[13]  Y. Ilan.  Microtubules: From understanding their dynamics to using them as potential therapeutic targets , 2018, Journal of cellular physiology.

[14]  K. Shailubhai,et al.  Immunotherapy with oral administration of humanized anti‐CD3 monoclonal antibody: a novel gut‐immune system‐based therapy for metaflammation and NASH , 2018, Clinical and experimental immunology.

[15]  H. Ebinuma,et al.  Intestinal barrier regulates immune responses in the liver via IL-10-producing macrophages. , 2018, JCI insight.

[16]  A. Wree,et al.  NLRP3 inflammasome driven liver injury and fibrosis: Roles of IL‐17 and TNF in mice , 2018, Hepatology.

[17]  Y. Ilan,et al.  Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift , 2017, BMC Gastroenterology.

[18]  E. Almon,et al.  An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy. , 2017, Journal of immunological methods.

[19]  I. Raz,et al.  Oral Administration of β-Glucosylceramide for the Treatment of Insulin Resistance and Nonalcoholic Steatohepatitis: Results of a Double-Blind, Placebo-Controlled Trial. , 2017, Journal of medicinal food.

[20]  F. Tacke,et al.  Liver — guardian, modifier and target of sepsis , 2017, Nature Reviews Gastroenterology &Hepatology.

[21]  E. Almon,et al.  Oral administration of a non-absorbable plant cell-expressed recombinant anti-TNF fusion protein induces immunomodulatory effects and alleviates nonalcoholic steatohepatitis , 2016, World journal of gastroenterology.

[22]  Y. Ilan.  Review article: novel methods for the treatment of non‐alcoholic steatohepatitis – targeting the gut immune system to decrease the systemic inflammatory response without immune suppression , 2016, Alimentary pharmacology & therapeutics.

[23]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[24]  Y. Ilan.  Oral immune therapy: targeting the systemic immune system via the gut immune system for the treatment of inflammatory bowel disease , 2016, Clinical & translational immunology.

[25]  V. Kraus,et al.  Colchicine--Update on mechanisms of action and therapeutic uses. , 2015, Seminars in arthritis and rheumatism.

[26]  Y. Ilan,et al.  The gut microbiome as a target for regulatory T cell-based immunotherapy: induction of regulatory lymphocytes by oral administration of anti-LPS enriched colostrum alleviates immune mediated colitis , 2015, BMC Gastroenterology.

[27]  A. Lavy,et al.  Oral administration of non‐absorbable delayed release 6‐mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial , 2015, Clinical and experimental immunology.

[28]  P. Ferenci,et al.  Oral anti‐CD3 immunotherapy for HCV‐nonresponders is safe, promotes regulatory T cells and decreases viral load and liver enzyme levels: results of a phase‐2a placebo‐controlled trial , 2015, Journal of viral hepatitis.

[29]  Y. Ilan,et al.  Altered distribution of regulatory lymphocytes by oral administration of soy-extracts exerts a hepatoprotective effect alleviating immune mediated liver injury, non-alcoholic steatohepatitis and insulin resistance. , 2015, World journal of gastroenterology.

[30]  E. Israeli,et al.  Oral mixture of autologous colon-extracted proteins for the Crohn's disease: A double-blind trial. , 2015, World journal of gastroenterology.

[31]  I. Turgeman,et al.  Oral Administration of OKT3 MAb to Patients with NASH, Promotes Regulatory T-cell Induction, and Alleviates Insulin Resistance: Results of a Phase IIa Blinded Placebo-Controlled Trial , 2015, Journal of Clinical Immunology.

[32]  Shulin Li,et al.  The Role of the Liver in Sepsis , 2014, International reviews of immunology.

[33]  S. Haeryfar,et al.  A robust scoring system to evaluate sepsis severity in an animal model , 2014, BMC Research Notes.

[34]  Shan Li,et al.  Tumour necrosis factor alpha (TNF-α) genetic polymorphisms and the risk of autoimmune liver disease: a meta-analysis , 2013, Journal of Genetics.

[35]  L. Galluzzi,et al.  Decoding cell death signals in liver inflammation. , 2013, Journal of hepatology.

[36]  S. Xiong,et al.  High susceptibility to liver injury in IL‐27 p28 conditional knockout mice involves intrinsic interferon‐γ dysregulation of CD4+ T cells , 2013, Hepatology.

[37]  R. Flavell,et al.  IL-10 Mediated Regulation of Liver Inflammation during Acute Murine Cytomegalovirus Infection , 2012, PloS one.

[38]  H. Wunsch,et al.  Population Burden of Long‐Term Survivorship After Severe Sepsis in Older Americans , 2012, Journal of The American Geriatrics Society.

[39]  K. Langa,et al.  Long-term cognitive impairment and functional disability among survivors of severe sepsis. , 2010, JAMA.

[40]  R. Terkeltaub,et al.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. , 2010, Arthritis and rheumatism.

[41]  Y. Ilan.  Oral tolerance: can we make it work? , 2009, Human immunology.

[42]  I. Gomatos,et al.  Liver histology in ICU patients dying from sepsis: a clinico-pathological study. , 2008, World journal of gastroenterology.

[43]  O. Shibolet,et al.  A Double-Blind Clinical Trial for Treatment of Crohn's Disease by Oral Administration of Alequel™, A Mixture of Autologous Colon-Extracted Proteins: A Patient-Tailored Approach , 2006, The American Journal of Gastroenterology.

[44]  E. Elinav,et al.  Amelioration of non‐alcoholic steatohepatitis and glucose intolerance in ob/ob mice by oral immune regulation towards liver‐extracted proteins is associated with elevated intrahepatic NKT lymphocytes and serum IL‐10 levels , 2006, The Journal of pathology.

[45]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[46]  O. Shibolet,et al.  Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: results of a phase I clinical trial. , 2005, World journal of gastroenterology.

[47]  A. Nagler,et al.  Alleviation of chronic GVHD in mice by oral immuneregulation toward recipient pretransplant splenocytes does not jeopardize the graft versus leukemia effect. , 2005, Human immunology.

[48]  Y. Ilan,et al.  Oral immune regulation: a novel method for modulation of anti-viral immunity. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[49]  O. Shibolet,et al.  Suppression of Hepatocellular Carcinoma Growth via Oral Immune Regulation towards Tumor-Associated Antigens Is Associated with Increased NKT and CD8+ Lymphocytes , 2004, Oncology.

[50]  J. Bion,et al.  Epidemiology and outcome of acute lung injury in European intensive care units , 2003, Intensive Care Medicine.

[51]  D. Gouma,et al.  Endogenous interferon γ protects against cholestatic liver injury in mice , 2002 .

[52]  F. Di Virgilio,et al.  Proinflammatory cytokines inhibit secretion in rat bile duct epithelium. , 2001, Gastroenterology.

[53]  A. Nagler,et al.  Oral tolerization ameliorates liver disorders associated with chronic graft versus host disease in mice , 2000, Hepatology.

[54]  I. Gotsman,et al.  Liver‐associated lymphocytes expressing NK1.1 are essential for oral immune tolerance induction in a murine model , 1999, Hepatology.

[55]  M. Ott,et al.  Oral tolerization to adenoviral proteins permits repeated adenovirus‐mediated gene therapy in rats with pre‐existing immunity to adenoviruses , 1998, Hepatology.

[56]  A. Schattner,et al.  Triple Anti-TNF-α Therapy in Early Sepsis: A Preliminary Report , 1997 .

[57]  S. Küsters,et al.  Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. , 1996, Gastroenterology.